Study Continues To Expand, Drive Commercialization Of Company’s Eluting Patch Technology To LPs, Consumer Product And Pharmaceutical Companies
BALTIMORE, MD, April 01, 2019 (GLOBE NEWSWIRE) — GREATER CANNABIS COMPANY (OTCQB: GCAN), a market leader and innovator in the development and commercialization of cannabinoid delivery systems, has announced today that it will launch a new clinical study to determine cannabidiol (CBD) absorption using its patented eluting patch technology. The new study will help drive the continued development and success of its delivery system and expand its commercialization to LPs, consumer product and pharmaceutical companies.
“There is an increasing demand for alternative routes of CBD administration among patients, providers and consumers who want safer, more convenient alternatives to inhaling, and more effective means than traditional ingestion,” said Aitan Zacharin, CEO of Greater Cannabis. “Our technology provides a solution. The new clinical study will help demonstrate this.”
The Company is spearheading the clinical study under its research and development arm, GCANRx, which is focused on developing innovative delivery technologies. The Company’s eluting transmucosal patch (ETP) uses a bio-adhesive, adjustable dose, fully dissolvable and non-irritant film that can be placed inside the cheek for needle free, intra-oral systemic delivery of CBD and other drugs. It enables absorption through the mucous membrane of the mouth, which can allow compounds to reach the bloodstream faster than other administration methods. The technology has been successful in achieving nearly 50% bioavailability with other compounds, which has been substantiated through clinical studies funded in part by the National Institutes of Health (NIH). The new clinical study will further determine its absorption of CBD and help drive the company’s continued market reach and development.
“A number of factors contribute to CBD bioavailability, making it notoriously difficult to get into the bloodstream,” added Zacharin. “Our continued efforts to test and develop our technology leverages science and data to help meet an unmet demand and need in the market for more effective, safe, and controlled delivery of cannabinoids.”
GCANRx expects to begin the new clinical study this month. For more information about the company and its technology, visit www.gcanrx.com.
About The Greater Cannabis Company:
The Greater Cannabis is a biopharmaceutical company focused on the development and commercialization of innovative cannabinoid delivery systems. Greater Cannabis deploys its patented technology platform for use in the cannabis industry. The Company’s conveyance platform can be utilized to deliver cannabinoids without the harmful side effects found with other routes of cannabinoid administration. The technology is versatile in that for the first-time patients can receive lower dosing, enhanced bioavailability, and controlled rapid and delayed release using a fully dissolvable, non-irritant oral eluting patch. Greater Cannabis’ mission is to bring our technology to the global market through partnerships with leading cannabis and pharmaceutical companies, for the benefit of patients and consumers. More information on the Greater Cannabis Company and its technology can be found on the Company’s website, www.gcanrx.com.
Disclaimer: Greater Cannabis Company relies upon the Safe Harbor Laws of 1933, 1934 and 1995 for all public news releases. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are necessarily estimates reflecting the company’s best judgment based upon current information and involve several risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors. Factors which could cause actual results to differ materially from those estimated by the company include, but are not limited to, government regulation; managing and maintaining growth; the effect of adverse publicity; litigation; competition; and other factors which may be identified from time to time in the company’s public announcements.